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The dose of efavirenz during concomitant rifampin (RMP) administration is a matter of debate. We studied
the influence of RMP coadministration on the steady-state pharmacokinetics of efavirenz in human immuno-
deficiency virus type 1 (HIV-1)-infected patients in South India. Fifty-seven HIV-tuberculosis (TB)-coinfected
and 15 HIV-1-infected patients receiving combination antiretroviral therapy (CART) with an efavirenz (600 mg
once daily)-containing regimen were recruited. HIV-TB-coinfected patients were receiving treatment with
RMP-containing regimens. A complete pharmacokinetic study was conducted with 19 HIV-TB patients on two
occasions (with and without RMP). Trough concentrations of efavirenz were measured in the remaining 38
patients during RMP coadministration. The 15 HIV-infected patients underwent complete pharmacokinetic
sampling on one occasion. Plasma efavirenz was estimated by high-performance liquid chromatography, and
genotyping of CYP2B6 G516T polymorphism was performed by sequencing. Peak and trough concentrations
and exposure to efavirenz were significantly higher in TT than in GT and GG genotype patients (P < 0.001).
Although RMP coadministration decreased the peak and trough concentrations and exposure to efavirenz by
17.8, 20.4, and 18.6%, respectively, the differences were not statistically significant. The trough concentration
of efavirenz was subtherapeutic (less than 1.0 g/ml) in 6 (8%) of 72 patients. In this South Indian population
of HIV-infected patients, CYP2B6G516T polymorphism but not RMP coadministration significantly influenced
the pharmacokinetics of efavirenz; patients with the TT genotype had very high blood levels of efavirenz. While
a small proportion of patients had subtherapeutic efavirenz levels, the clinical implications are uncertain, as
all had good immunological responses to CART.
Tuberculosis (TB) remains one of the most important op-
portunistic infections in human immunodeficiency virus (HIV)-
infected individuals. The burden of effectively treating HIV-
TB-coinfected patients is a well-recognized global public
health problem. A decreased risk of death has been observed
in patients starting combination antiretroviral therapy (CART)
compared with those not receiving CART after the diagnosis
of TB (2, 9, 13). In India, there are effective treatments avail-
able for both HIV disease and TB through the government
program. Concomitant administration of CART and anti-TB
medications is often complicated because of drug-drug inter-
actions and the adverse-effect profile (17, 30, 36).
Efavirenz (EFV) is a potent nonnucleoside reverse trans-
criptase inhibitor for the treatment of HIV type 1 (HIV-1)
infection. EFV has been recommended as a first-line option in
antiretroviral therapy (ART) and the preferential choice in
TB- and HIV-coinfected patients, despite induction of the
cytochrome P-450 system by rifampin (RMP). The available
pharmacokinetic data provide evidence of a 13 to 25% reduc-
tion in EFV levels when it is coadministered with RMP (20),
which is lower than those of nevirapine (40%) and protease
inhibitors (80 to 95%) (7). Although effective pharmacological,
clinical, immunological, and virologic responses have been re-
ported with a 600-mg dose of EFV (11, 22, 27, 28), the ade-
quacy of this dose during concomitant treatment with RMP
remains a matter of debate. In fact, after reviewing the current
literature, the FDA concluded that the available data are in-
sufficient to support definitive dosing recommendations for the
coadministration of EFV and RMP (10). Differences in pa-
tients’ body weights appear to cause further differences in
exposure to EFV, raising the question of whether the EFV
dose should be increased in people with higher body weights
(20, 26).
Several factors could alter the pharmacokinetics of EFV.
Sex is reported to have a modest influence on the pharmaco-
kinetic profiles of certain antiretroviral drugs, including EFV
(6, 29). A single nucleotide polymorphism at position 516 on
the CYP2B6 gene has been widely reported to influence the
pharmacokinetics of EFV (3, 14, 18, 19, 31, 32, 33, 38, 39).
India has a large number of HIV-infected individuals, and
access to ART is improving. With an increasing number of
patients receiving treatment, it is important to study the phar-
macokinetics of EFV, which is extensively used, particularly by
HIV-TB-coinfected patients. No information is available on
the pharmacokinetics of EFV in HIV-infected patients in In-
dia, who are genetically different from the other ethnic groups
studied so far. Herein we report the influences of sex, body
weight, CYP2B6 G516T polymorphism, and RMP coadminis-
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tration on the steady-state pharmacokinetics of EFV in HIV-
infected patients in an ethnic South Indian population.
MATERIALS AND METHODS
Patients. Seventy-two HIV-infected patients (57 with active TB) who were
attending the outpatient clinic at the Government Hospital of Thoracic Medi-
cine, Tambaram, India, during March to July 2006 took part in this study. All of
the patients lived in the state of Tamil Nadu in South India, were adults, and
weighed more than 30 kg. They were undergoing treatment regularly with EFV
(600 mg/day) along with lamivudine (150 mg twice a day) and stavudine (30/40
mg twice a day) or zidovudine (300 mg twice a day) for a minimum period of 1
week. In addition, HIV-TB-coinfected patients were receiving treatment regu-
larly for TB for a minimum period of 2 weeks. Their anti-TB treatment (ATT)
regimen consisted of RMP (450 mg for patients with body weights of 60 kg and
600 mg for those with body weights of60 kg), isoniazid (600 mg), pyrazinamide
(1,500 mg), and ethambutol (1,200 mg) thrice weekly for 2 months, followed by
RMP and isoniazid thrice weekly for 4 months at the same doses. Only those
patients who expressed a willingness to participate in the study and agreed to give
informed written consent were recruited. Chronic alcoholics and females on
hormonal birth control pills were not included in the study. The study com-
menced after the approval of the Institutional Ethics Committee was obtained.
Design and conduct of the study. The study was conducted at the Government
Hospital of Thoracic Medicine, Chennai, India. Eligible patients were admitted
to the hospital at least a day prior to the study. Informed written consent was
obtained from all of the patients.
Details of patient recruitment and the tests performed are shown in Fig. 1. A
single blood collection at 24 h after EFV administration (trough level) was done
for 38 HIV-TB patients while they were receiving treatment for HIV and TB. A
complete pharmacokinetic study was conducted with 34 patients. Of these, 19
who had concurrent TB were investigated on two occasions; the first occasion
was while the patients were receiving treatment for HIV and TB, and the second
occasion was at least 1 month after stopping ATT. A crossover design was
employed in which each patient served as his own control. The remaining 15
HIV-infected patients without TB were investigated only on one occasion.
On the day of the study, blood samples (3 ml) were drawn in heparinized
Vacutainer tubes before dosing and serially at 1, 2, 4, 6, 8, 12, and 24 h after
dosing. An additional sample (1 ml) was collected in an EDTA Vacutainer tube
at any one time point during the pharmacokinetic study from all of the patients.
This sample was drawn when the patients were not receiving RMP.
The heparinized blood samples were centrifuged immediately, and plasma was
stored at 20°C until estimation of EFV was carried out. The EDTA blood
sample was used for DNA extraction and genotyping of CYP2B6 G516T poly-
morphism.
Estimation of plasma EFV. Estimation of plasma EFV was performed by
high-performance liquid chromatography with UV detection (Shimadzu Corpo-
ration, Kyoto, Japan) according to a validated method (32).
Genotyping of CYP2B6 G516T polymorphism. The genetic characterization of
the CYP2B6 gene was performed with genomic DNA extracted from whole
blood. A 204-bp fragment in exon 4 of the CYP2B6 gene containing the target
site (position 516) was amplified by a single round of PCR with CYP2B6 Forward
Primer 5 CTTGACCTGCTGCTTCTTCC 3 and CYP2B6 Reverse Primer 5
TCCCTCTCCGTCTCCCTG 3 (1).
The amplicon was directly sequenced with a 3100 Avant Genetic analyzer
(Applied Biosystems).
Pharmacokinetic analysis. Pharmacokinetic variables such as the maximum or
peak concentration (Cmax), the minimum or trough concentration (Cmin), the
time to attain Cmax, exposure or area under the concentration-time curve from 0
to 24 h (AUC0-24), apparent oral clearance (CL), and half-life were calculated by
a noncompartmental model with WinNonlin software (version 5.1; Pharsight
Corporation, Mountain View, CA).
Statistical evaluation. Analysis of data was performed with the SPSS (version
14) package. Differences in the pharmacokinetic parameters of EFV between
males and females were studied by using the t test. The Wilcoxon signed-rank test
(paired test) was used to determine the significance of differences in the phar-
macokinetic variables of EFV with and without RMP. Pearson’s test was used to
determine the correlation between body weight and the pharmacokinetic param-
eters of EFV. Groupwise comparisons of certain pharmacokinetic variables of
EFV among the CYP2B6 G516T genotype patients were done by using Tukey’s
multiple-comparison test. Deviation of genotype frequencies from Hardy-Wein-
berg equilibrium expectations was evaluated by using the chi-square test. Allelic
frequency was estimated by dividing the total number of copies of individual
alleles by all of the alleles in the population. A P value of 0.05 was considered
statistically significant.
RESULTS
The demographic details of all of the patients are given in
Table 1. HIV and HIV-TB patients were similar with respect
to age, body weight, pre-CART CD4 cell counts, and duration
of ART. There were more males in both groups of patients.
The effect of RMP on the pharmacokinetics of EFV was
studied in 19 HIV-TB patients who were investigated on two
occasions, that is, during ATT with RMP-containing regimens
and at least 1 month after stopping ATT. Pharmacokinetic
variables of EFV were compared on the two occasions. Except
for four patients, all had higher blood levels of EFV after
stopping ATT than during ATT. Although RMP lowered the
Cmax, Cmin, and AUC0-24 of EFV and increased the clearance
of the drug, the differences were not statistically significant.
The mean percent decreases in Cmax, Cmin, and AUC0-24 were
17.8, 20.4, and 18.6%, respectively (Table 2).
Trough concentrations of EFV were available for 57 patients
during concomitant RMP treatment (19 patients who took part
in the two-occasion pharmacokinetic study and 38 patients for
whom a single blood collection at 24 h after EFV administra-
tion was performed) and 34 patients without RMP (19 patients









Age (yr) 36.8 (26–56)a 36.0 (26–56) 35.1 (26–52)
No. of males 63 53 10
Body wt (kg) 50.4 (34–75) 49.2 (34–75) 50.4 (34–69)
Pre-CART CD4 count
(cells/mm3)
98 (1–304) 111 (1–304) 91 (13–192)
Duration of CART (mo) 5.1 (0.3–17) 5.4 (0.3–17) 4.5 (0.3–14)
a The values shown are means (ranges).
FIG. 1. Details of patient recruitment to the study.











who took part in the two-occasion pharmacokinetic study and
15 patients in the one-occasion pharmacokinetic study). The
mean Cmins of EFV in the 57 and 34 patients were 4.39 and
4.37 g/ml, respectively. Considering all 72 patients (15 HIV
and 57 HIV-TB patients) recruited for the study, the trough
concentration of EFV was subtherapeutic (less than 1.0 g/ml)
in 6 patients (8%); 2 of them were not on RMP, while 4 were
receiving RMP at the time of the study. The mean CD4 cell
counts at the start of ART (baseline) in the 72 patients was 98
(range, 1 to 304) cells/mm3. This increased to 304 (range, 32 to
925) cells/mm3 at 6 months in 30 patients and 366 (range, 153
to 582) cells/mm3 in 25 patients, respectively.
There were 25 males and 9 females among the 34 patients
who took part in the pharmacokinetic study. Comparisons of
pharmacokinetic variables of EFV between males and females
were made while they were not receiving ATT. Although males
had higher Cmax (7.48 versus 6.02 g/ml), Cmin (4.1 versus 2.71
g/ml), and AUC0-24 (120.48 versus 85.13 g/ml  h) values,
the differences were not statistically significant. There was a
positive correlation between patients’ body weights and EFV
clearance; this was statistically significant (r 0.37, P 0.034).
The pharmacokinetic variables of EFV, such as Cmax, Cmin,
AUC0-24, and CL, calculated for 34 patients were highly cor-
related (r  0.9, P  0.001).
Of the 34 patients who underwent complete pharmacoki-
netic sampling, CYP2B6 G516T genotyping could be per-
formed for 25 patients. Among these, the numbers with the
GG, GT, and TT genotypes were 10, 8, and 7, respectively. The
G and T allele frequencies were 0.56 and 0.44, respectively.
When a 2 test of observed versus predicted genotype frequen-
cies was conducted, the polymorphism was found to be in
Hardy-Weinberg equilibrium. The mean Cmax, Cmin, and
AUC0-24 of EFV were significantly higher and the CL was
lower in TT genotype patients than in GG and GT genotype
patients (P  0.001). The distribution of EFV AUC0-24 values
among patients with the three genotypes is shown in Fig. 2.
DISCUSSION
Pharmacokinetic variations due to several factors could lead
to heterogeneity in the response to ART. In India, patients
with TB (with or without HIV coinfection) are treated with a
standard 6-month intermittent anti-TB regimen (4). The stan-
dard antiretroviral regimen employed for such patients consists
of EFV with two nucleoside reverse transcriptase inhibitors.
Supportive evidence for a definitive dosing recommendation
for EFV coadministered with RMP remains limited. While
there have been suggestions to use EFV at a dose of 800
mg/day when giving it along with RMP (15), observational
studies have shown that EFV at 600 mg/day is sufficient for
most HIV-infected patients (11, 22, 27, 28). There are few
clinical studies on the pharmacokinetic effect of RMP on
plasma EFV levels (20, 26). These studies have shown that
patients with higher body weights have reduced plasma EFV
concentrations and suggested that it is advisable to increase the
dose of EFV to 800 mg/day when coadministering it with RMP
to patients weighing 60 kg. However, the safety and tolera-
bility of the higher dose are a matter of concern (5). This
becomes more complicated because of variability in pharma-
cokinetics, therapeutic response, and side effects in patients
belonging to different racial and ethnic groups (33).
This study reports, for the first time, the steady-state phar-
macokinetics of EFV in HIV-infected patients in South India.
Our findings showed that RMP coadministration did not sig-
nificantly alter the pharmacokinetics of EFV. Further, the
trough concentration of EFV remained within the therapeutic
range of the drug (1.0 g/ml) in the majority of the patients
(66 of 72). Four patients had lower blood EFV levels after
stopping ATT than during concomitant ATT. The reasons for
this reverse trend are unclear and could be a function of the
wide intraindividual variability of this drug; similar findings
have been reported by others (11, 20). All of the patients who
took part in this study were taking ART regularly, as assessed
by the medical officer based on their monthly visit to the
hospital to collect their drugs and by pill counting. Among the
six patients with subtherapeutic trough levels, four were receiv-
ing RMP. Hence, 2 of 15 HIV and 4 of 57 HIV-TB patients
had EFV trough levels of 1.0 g/ml. The numbers of GG,
GT, and TT genotype patients in this group were two, two, and
one, respectively. The CYP2B6 genotype status of one patient
was not known. Five patients showed a good immunological
TABLE 2. Steady-state pharmacokinetics of EFV with and without RMPa
Treatment Cmax Cmin Tmax AUC(0-24) CL t1/2
EFV 9.88 	 9.38 5.84 	 7.54 2.53 	 1.07 169.77 	 205.34 7.25 	 5.10 24.98 	 13.19
EFV  RMP 8.12 	 7.10 4.65 	 5.80 2.47 	 0.97 138.19 	 148.28 9.27 	 6.52 17.57 	 9.42b
a The values shown are means 	 standard deviations for 19 patients. Tmax, time to attain Cmax; t1/2, half-life.
b P  0.05.
FIG. 2. Plasma exposure to EFV in the different genotypes of
CYP2B6 G516T polymorphism. A scatter diagram of the distribution
of plasma exposures to EFV in patients with different CYP2B6 G516T
genotypes is shown. The numbers of GG, GT, and TT genotype pa-
tients were 10, 8, and 7, respectively.











response following ART, while one died. Neither RMP coad-
ministration nor the GG or GT genotype seemed to correlate
with subtherapeutic EFV levels, and hence it is not possible to
attribute any specific reason for EFV levels to fall below the
therapeutic range in these six patients. Further, while an EFV
trough level of 1.0 g/ml is generally accepted as the threshold
above which EFV levels must be maintained, the supporting
data for this come from the study of Marzolini et al. (25);
however, this threshold may be higher than is required for
virologic suppression.
Our study findings do not support increasing the dose of
EFV when coadministering it with RMP. Although concomi-
tant RMP administration lowered the peak concentration and
exposure to EFV by about 18%, this did not seem to have any
adverse impact on the immunological outcomes. This is in
agreement with that suggested by others, who observed excel-
lent clinical outcomes when giving EFV at 600 mg/day to pa-
tients receiving RMP (11, 22, 27, 28). A study conducted with
HIV-TB patients receiving EFV at 600 mg/day and RMP re-
ported virological success in about 80% of the patients studied
at 48 weeks of treatment (24). In a comparative study of two
groups of HIV-infected patients receiving EFV at 600 and 800
mg/day, Manosuthi et al. did not observe any difference in
plasma EFV levels and time to virological success (23). A
similar viewpoint has been put forth by Lo´pez-Corte´s et al.,
who did not observe a relationship between the EFV trough
concentration and virological efficacy at a dose of 800 mg/day,
indicating that a firm recommendation cannot be made to
increase the dose of EFV when concomitantly giving it with
RMP (21).
It has been reported that patients with higher body weights
have lower blood levels of EFV and that such patients would
require a higher dose of the drug, particularly during concom-
itant RMP treatment (20, 26). Our study did not observe any
significant correlation between body weight and EFV peak and
trough concentrations and exposure. Our study findings also
showed that sex did not alter the pharmacokinetic profile of
EFV. This is in agreement with those reported by Ribaudo et
al. (33) and Rodriguez-Novoa et al. (34) but disagrees with the
findings of others (6, 29).
Several polymorphisms in the gene CYP2B6 may influence
isoenzyme activity (18) and therefore the hepatic clearance of
EFV. The most significant allelic variant that is reported to
influence plasma concentrations of EFV is a G-to-T change at
codon 516 (that is, a 516 G3T single-nucleotide polymor-
phism) (3, 14, 18, 19, 33, 34, 35, 38, 39), while other reported
polymorphisms include CYP2B6 T983C, CYP3A4 A392G, and
CYP3A5 A6986G (14, 38, 40). We studied only the CYP2B6
G516T polymorphism and found that TT genotype patients
had significantly elevated blood EFV and drug exposure levels
than GG and GT genotype patients. This indicates that phar-
macogenetic variations lead to pharmacokinetic differences
and that this polymorphism influences the pharmacokinetics of
EFV in the Indian population too. Our study was underpow-
ered to observe if changes in EFV pharmacokinetics in re-
sponse to RMP differed based on genotype. It would be inter-
esting to study the impact of other CYP polymorphisms on
EFV pharmacokinetics.
The peak and trough concentrations and exposure to EFV
observed in the Indian patients were considerably higher than
those reported by Lo´pez-Corte´s et al. in the Spanish popula-
tion (20) and by Haas et al. in African Americans, Hispanics,
and European Americans (14). Similar findings with respect to
plasma nevirapine levels were observed in a previous study of
ours (31). It is of interest that in spite of the concomitant use
of EFV and RMP, the peak concentration of EFV was 4
g/ml in 11 of 19 patients, and no serious adverse events were
reported in any of these patients. In this study, TT genotype
patients accounted for 28% of the total (7 of 25 patients),
which is similar to that reported by Kwara et al., who observed
that 27% of West African patients (7 of 26) had the TT geno-
type (18). We obtained a T allele frequency of 0.44, which is
higher than that reported in Koreans (0.14), Japanese (0.16),
Caucasians (0.25), white Americans (0.25), and African Amer-
icans (0.28) but similar to that of West Africans (0.42), Chinese
(0.43), and Hispanics (0.43) (8, 16, 37). However, the number
of patients genotyped for CYP2B6 G516T polymorphism was
quite small. Although TT genotype patients were distinct from
GG and GT genotype patients with respect to plasma exposure
to EFV (Fig. 2), there was a clear split among the TT genotype
patients; three patients had very high plasma exposure levels.
The possible reason for this dramatic split could be the wide
interpatient variability associated with plasma levels of EFV or
the interplay of other polymorphisms such as CYP2B6 T983C,
which is also reported to influence EFV pharmacokinetics
(40). Thus, a high proportion of patients in South India would
have high blood levels of EFV. Hence, the time may have come
for clinical trials with lower doses of EFV. In fact, the feasi-
bility of genotype-based EFV dose reduction in CYP2B6
G516T allelic carriers was studied and found to relieve patients
of EFV-associated central nervous system symptoms (12).
Such studies are important, because they would have cost-
saving implications for developing countries, apart from the
reduction in adverse events for individual patients. In fact, the
study of Wyen et al. on CYP2B6 T983C polymorphism and
plasma EFV reported that homozygote patients (CC genotype
patients) discontinued therapy within 1 week because of cen-
tral nervous system toxicity (40).
One limitation of this study was that we could not do study
patient viral load measurements, which would have enabled us
to relate variations in EFV pharmacokinetics to treatment
outcomes. Further, we studied the influence of only a single
nucleotide polymorphism, 516 G3T, in the CYP2B6 gene;
plasma levels of EFV are probably influenced by other poly-
morphisms, especially CYP2B6 983 T3C (40). In conclusion,
this cross-sectional study has shown that CYP2B6 G516T poly-
morphism influences the pharmacokinetics of EFV. While
concomitant RMP treatment reduces plasma levels of EFV by
about 18%, this was not statistically significant. Moreover, only
a small proportion of patients had subtherapeutic trough con-
centrations, suggesting that the dose of EFV may not need to
be increased. Future studies need to examine more closely the
minimum acceptable trough level of EFV for the maintenance
of antiretroviral efficacy to clarify the issue of optimal trough
levels. Our findings have implications for government pro-
grams employing standard ART regimens, as dosage changes
for some patients present substantial logistic and clinical chal-
lenges. Prospective studies are in progress that would correlate
EFV trough concentrations with virological and immuno-











logical outcomes in patients undergoing treatment for HIV
and TB.
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